Gestational diabetes (GDM) is associated with negative outcomes for both mother and child in a short and long term perspective.
There is ongoing debate about diagnostic criteria for GDM, and in 2015 the Swedish National Board of Health published recommendations for what glucose levels during pregnancy should be treated. These guidelines (tresholds for treatment) were the same as the WHO recommendation from 2013.
The CDC4G study is a "stepped-wedge" randomised trial, where in 2018 11 clinics in Sweden changed their guidelines for diagnostic criteria using the same treatment and surveillance guidelines. Data has been collected through the National Pregnancy Register (www.graviditetsregistret.se) , other national health registers and study eCRF. The study is supported by SNAKS (www.sfog.se) and has received a large National Governemnt funded grant.
Due to the Covid-19 pandemic the study results are delayed, but data management is now ongoing and during 2022 the first main results are planned to be ready together with a health economic evaluation.
We hope the study results will give us more evidence on how treating lower diagnostic tresholds for GDM effect pregnancy outcomes in Sweden, where screening for GDM is mostly based on risk factors and random blood glucose values.
The CDC4G study is registered at ISRCTN with study ID ISRCTN41918550 (15/12/2017).
Project leader is Helena Fadl
Assoc Prof, Senior Consultant
Dept of Obstetrics and Gyneocology
University Hospital Örebro
Contact:
Helena Fadl, projectleader: helena.fadl@regionorebrolan.se
Karin Hildén, senior consultant: karin.hilden@regionorebrolan.se
Birgitta Pettersson,research admin: birgitta.pettersson2@regionorebrolan.se